Comparative Pharmacology
Head-to-head clinical analysis: ETHAMBUTOL HYDROCHLORIDE versus MYCOBUTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHAMBUTOL HYDROCHLORIDE versus MYCOBUTIN.
ETHAMBUTOL HYDROCHLORIDE vs MYCOBUTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits arabinosyl transferase (emb) involved in cell wall synthesis of mycobacteria, specifically inhibiting polymerization of arabinose into arabinan, a component of arabinogalactan.
Inhibits DNA-dependent RNA polymerase in Mycobacterium tuberculosis, blocking RNA synthesis.
15 mg/kg orally once daily (range 15-25 mg/kg); typically 800-1600 mg daily.
300 mg orally once daily, or 300 mg twice weekly for MAC prophylaxis in HIV. For TB, 300 mg daily as part of combination therapy.
None Documented
None Documented
3–4 hours in normal renal function; prolonged to 7–15 hours in moderate renal impairment and up to 30 hours in severe renal impairment; clinical context: requires dosing adjustment when creatinine clearance <30 mL/min.
Terminal elimination half-life: 35-40 hours (range 30-50 hours). Clinical context: Allows once-daily dosing; prolonged in hepatic or renal impairment.
Renal: ~80% as unchanged drug and metabolites via glomerular filtration and tubular secretion; fecal: ~15%; biliary: <2%.
Renal (30% as unchanged drug), fecal (50-60% as metabolites and parent compound), biliary (minor).
Category A/B
Category C
Antimycobacterial
Antimycobacterial